Dr Andy Stein

Empagliflozin: transforming kidney care

Empagliflozin: transforming kidney care In a recent trial, the EMPA-Kidney group, 2023 showed the significant benefits of SGLT2is in CKD patients. Why is this important? Chronic kidney disease (CKD) affects millions globally, posing a risk for kidney failure and heart issues. Enter empagliflozin, initially used for diabetes but now under the spotlight for potentially safeguarding […]

Empagliflozin: transforming kidney care Read More »

10 (more) unanswered questions in nephrology, CKD and transplantation

10 (more) unanswered questions in nephrology, CKD and transplantation In this article, we will describe 10 (more) unanswered questions in nephrology, CKD and transplantation. CKD 1. Why are we not deprescribing in nephrology? In the era of deprescribing, there is recognition that polypharmacy is common in nephrology, and an issue for many of our patients.

10 (more) unanswered questions in nephrology, CKD and transplantation Read More »

10 unanswered questions in nephrology, CKD and transplantation

10 unanswered questions in CKD, nephrology and transplantation There are many. So the ones described below are just a start. Nonetheless we will now describe 10 unanswered questions in CKD, nephrology and transplantation. CKD 1. What are the toxins in CKD? This perhaps the simplest but most important question in nephrology. Disappointingly [“yes, very”, CKDEx

10 unanswered questions in nephrology, CKD and transplantation Read More »

New study of ‘double matching’ tissue type for kidney transplant patients

New study of ‘double matching’ tissue type for kidney transplant patients Scientists are to start ‘double matching’ tissue type for kidney transplant recipients – in a bid to make sure the donated kidney is less likely to be rejected. If the six-month pilot scheme at Hammersmith Hospital in London is a success then the initiative

New study of ‘double matching’ tissue type for kidney transplant patients Read More »

Scroll to Top